Liyang Yin
Hengyang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Deubiquitinase UCH-L1 confers paclitaxel resistance via stabilizing PKM2 to promote glycolysis in triple-negative breast cancer.
Journal: Cell death & disease
Published: July 03, 2025
DCC-2036 induces repolarization of TAMs to M1 type and enhances CD8+ T cell immunity in TNBC.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: May 09, 2025
DCC-2036 inhibits osteosarcoma via targeting HCK and the PI3K/AKT-mTORC1 axis to promote autophagy.
Journal: World journal of surgical oncology
Published: January 09, 2025
Recent advances in hematopoietic cell kinase in cancer progression: Mechanisms and inhibitors.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: March 25, 2024
FUNDC2, a mitochondrial outer membrane protein, mediates triple-negative breast cancer progression via the AKT/GSK3β/GLI1 pathway.
Journal: Acta biochimica et biophysica Sinica
Published: September 13, 2023
The emerging roles of metabolism in the crosstalk between breast cancer cells and tumor-associated macrophages.
Journal: International journal of biological sciences
Published: May 10, 2023
Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer.
Journal: Frontiers in immunology
Published: October 21, 2021
Identification of an AXL kinase inhibitor in triple-negative breast cancer by structure-based virtual screening and bioactivity test.
Journal: Chemical biology & drug design
Published: July 12, 2021
Knockdown of ZBTB7A inhibits cell proliferation of breast cancer through regulating the ubiquitination of estrogen receptor alpha.
Journal: Life sciences
Published: August 30, 2019
Showing 1-9 of 9
Last Updated: 09/26/2026